CL2017003273A1 - Inmunoglobulinas conjugadas en cys80 - Google Patents
Inmunoglobulinas conjugadas en cys80Info
- Publication number
- CL2017003273A1 CL2017003273A1 CL2017003273A CL2017003273A CL2017003273A1 CL 2017003273 A1 CL2017003273 A1 CL 2017003273A1 CL 2017003273 A CL2017003273 A CL 2017003273A CL 2017003273 A CL2017003273 A CL 2017003273A CL 2017003273 A1 CL2017003273 A1 CL 2017003273A1
- Authority
- CL
- Chile
- Prior art keywords
- immunoglobulins
- cys80
- conjugated
- reacts
- thiol
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 8
- 102000018358 immunoglobulin Human genes 0.000 title abstract 8
- 229940072221 immunoglobulins Drugs 0.000 title abstract 5
- 150000003573 thiols Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001268 conjugating effect Effects 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se proporcionan métodos para generar inmunoglobulinas conjugadas, en donde el método comprende: desbloquear una cisteína en la posición de aminoácido 80 (“Cys80”) en una región variable de la cadena liviana de una inmunoglobulina, en donde la inmunoglobulina comprende una región variable de la cadena pesada y la región variable de la cadena liviana; y conjugar un compuesto que reacciona con tiol en Cys80, en donde el compuesto que reacciona con tiol comprende un grupo que reacciona con tiol. También se proporcionan moléculas de fijación al antígeno y métodos para generarlas, inmunoglobulinas al igual que moléculas de ácido nucleico que codifican las inmunoglobulinas y células huésped que comprenden las moléculas de ácido nucleico, inmunoglobulinas conjugadas y regiones variables de la cadena liviana para usar en una inmunoglobulina conjugada.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562182020P | 2015-06-19 | 2015-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017003273A1 true CL2017003273A1 (es) | 2018-12-21 |
Family
ID=56404289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017003273A CL2017003273A1 (es) | 2015-06-19 | 2017-12-19 | Inmunoglobulinas conjugadas en cys80 |
Country Status (33)
Country | Link |
---|---|
US (3) | US10273310B2 (es) |
EP (2) | EP3795591B1 (es) |
JP (2) | JP6823606B2 (es) |
KR (1) | KR20180021807A (es) |
CN (1) | CN107949575B (es) |
AU (1) | AU2016280190B9 (es) |
BR (1) | BR112017027252A2 (es) |
CA (1) | CA2989637C (es) |
CL (1) | CL2017003273A1 (es) |
CO (1) | CO2017013303A2 (es) |
CY (1) | CY1123481T1 (es) |
DK (2) | DK3310816T3 (es) |
ES (2) | ES2829251T3 (es) |
HK (1) | HK1252625A1 (es) |
HR (1) | HRP20201489T1 (es) |
HU (2) | HUE064407T2 (es) |
IL (1) | IL256263B (es) |
LT (1) | LT3310816T (es) |
MA (1) | MA44207B1 (es) |
MD (1) | MD3310816T2 (es) |
MX (1) | MX2017016674A (es) |
MY (1) | MY189024A (es) |
PE (1) | PE20180498A1 (es) |
PH (1) | PH12017502352A1 (es) |
PL (1) | PL3310816T3 (es) |
PT (1) | PT3310816T (es) |
RS (1) | RS60943B1 (es) |
RU (1) | RU2756101C2 (es) |
SG (1) | SG10201913935RA (es) |
SI (1) | SI3310816T1 (es) |
UA (1) | UA124830C2 (es) |
WO (1) | WO2016205618A1 (es) |
ZA (2) | ZA201708619B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4055053A1 (en) | 2019-11-07 | 2022-09-14 | Eisai R&D Management Co., Ltd. | Anti-mesothelin eribulin antibody-drug conjugates and methods of use |
JP7399305B2 (ja) * | 2020-02-12 | 2023-12-15 | イーライ リリー アンド カンパニー | 抗体または抗原結合フラグメントの結晶化 |
CA3184645A1 (en) | 2020-06-05 | 2021-12-09 | Eisai R&D Management Co., Ltd. | Anti-bcma antibody-drug conjugates and methods of use |
CN112694521B (zh) * | 2020-12-02 | 2023-01-17 | 杭州百凌生物科技有限公司 | 一种人工多肽lh、其抗体及在病理检测中的应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1187094C (zh) * | 1998-04-28 | 2005-02-02 | 应用研究系统Ars股份公司 | 多元醇干扰素β偶联物 |
US6904369B1 (en) * | 2000-06-29 | 2005-06-07 | The Trustees Of Columbia University In The City Of New York | Conjugated ligands for the stimulation of blood cell proliferation by effecting dimerization of the receptor for stem cell factor |
US7402409B2 (en) | 2003-01-23 | 2008-07-22 | Epitomics, Inc. | Cell fusion method |
AU2003259718A1 (en) | 2003-08-07 | 2005-03-07 | Epitomics, Inc. | Methods for humanizing rabbit monoclonal antibodies |
WO2006017759A2 (en) * | 2004-08-05 | 2006-02-16 | Kirin Brewery Co., Ltd. | Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
GB0428012D0 (en) * | 2004-12-22 | 2005-01-26 | Hammersmith Imanet Ltd | Radiolabelling methods |
JP5791895B2 (ja) * | 2007-05-04 | 2015-10-07 | テクノファージ, インベスティガサン エ デセンボルビメント エム ビオテクノロジア,エスエー | 遺伝子操作されたウサギ抗体可変ドメイン及びその使用 |
EP2162469A4 (en) * | 2007-05-21 | 2012-08-01 | Alderbio Holdings Llc | NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES |
US20110033378A1 (en) * | 2008-01-18 | 2011-02-10 | Medlmmune, Llc. | Cysteine Engineered Antibodies For Site-Specific Conjugation |
EP2842575B1 (en) | 2008-03-18 | 2017-09-27 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
WO2010118203A2 (en) | 2009-04-09 | 2010-10-14 | Morphotek, Inc. | Endosialin binding molecules |
CN114246952A (zh) * | 2010-06-08 | 2022-03-29 | 基因泰克公司 | 半胱氨酸改造的抗体和偶联物 |
AR082205A1 (es) * | 2010-07-12 | 2012-11-21 | Covx Technologies Ireland Ltd | Conjugados de anticuerpos multifuncionales |
CN102008732B (zh) * | 2010-11-08 | 2012-10-24 | 武汉华耀生物医药有限公司 | 一种叶酸偶联抗体药物及其制备方法与应用 |
CA2882753C (en) | 2012-08-21 | 2021-08-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
RS58928B1 (sr) * | 2012-08-29 | 2019-08-30 | Hoffmann La Roche | Transporter za krvno-moždanu barijeru |
EP3892294A1 (en) | 2013-08-28 | 2021-10-13 | AbbVie Stemcentrx LLC | Site-specific antibody conjugation methods and compositions |
-
2016
- 2016-06-17 PE PE2017002753A patent/PE20180498A1/es unknown
- 2016-06-17 KR KR1020187001769A patent/KR20180021807A/ko not_active Application Discontinuation
- 2016-06-17 ES ES16736952T patent/ES2829251T3/es active Active
- 2016-06-17 HU HUE20192124A patent/HUE064407T2/hu unknown
- 2016-06-17 CN CN201680035726.6A patent/CN107949575B/zh active Active
- 2016-06-17 WO PCT/US2016/038041 patent/WO2016205618A1/en active Application Filing
- 2016-06-17 SG SG10201913935RA patent/SG10201913935RA/en unknown
- 2016-06-17 PL PL16736952T patent/PL3310816T3/pl unknown
- 2016-06-17 US US15/185,879 patent/US10273310B2/en active Active
- 2016-06-17 DK DK16736952.9T patent/DK3310816T3/da active
- 2016-06-17 UA UAA201713079A patent/UA124830C2/uk unknown
- 2016-06-17 AU AU2016280190A patent/AU2016280190B9/en active Active
- 2016-06-17 MD MDE20180417T patent/MD3310816T2/ro unknown
- 2016-06-17 ES ES20192124T patent/ES2967613T3/es active Active
- 2016-06-17 MY MYPI2017001842A patent/MY189024A/en unknown
- 2016-06-17 DK DK20192124.4T patent/DK3795591T3/da active
- 2016-06-17 LT LTEP16736952.9T patent/LT3310816T/lt unknown
- 2016-06-17 JP JP2017565751A patent/JP6823606B2/ja active Active
- 2016-06-17 EP EP20192124.4A patent/EP3795591B1/en active Active
- 2016-06-17 HU HUE16736952A patent/HUE051315T2/hu unknown
- 2016-06-17 MA MA44207A patent/MA44207B1/fr unknown
- 2016-06-17 RU RU2017146220A patent/RU2756101C2/ru active
- 2016-06-17 BR BR112017027252-0A patent/BR112017027252A2/pt active Search and Examination
- 2016-06-17 RS RS20201246A patent/RS60943B1/sr unknown
- 2016-06-17 CA CA2989637A patent/CA2989637C/en active Active
- 2016-06-17 SI SI201630933T patent/SI3310816T1/sl unknown
- 2016-06-17 EP EP16736952.9A patent/EP3310816B1/en active Active
- 2016-06-17 MX MX2017016674A patent/MX2017016674A/es unknown
- 2016-06-17 PT PT167369529T patent/PT3310816T/pt unknown
-
2017
- 2017-12-12 IL IL256263A patent/IL256263B/en unknown
- 2017-12-18 PH PH12017502352A patent/PH12017502352A1/en unknown
- 2017-12-18 ZA ZA2017/08619A patent/ZA201708619B/en unknown
- 2017-12-19 CL CL2017003273A patent/CL2017003273A1/es unknown
- 2017-12-22 CO CONC2017/0013303A patent/CO2017013303A2/es unknown
-
2018
- 2018-09-17 HK HK18111926.6A patent/HK1252625A1/zh unknown
-
2019
- 2019-03-14 US US16/353,326 patent/US11129904B2/en active Active
-
2020
- 2020-07-28 JP JP2020127204A patent/JP7042876B2/ja active Active
- 2020-09-18 HR HRP20201489TT patent/HRP20201489T1/hr unknown
- 2020-10-20 CY CY20201100992T patent/CY1123481T1/el unknown
-
2021
- 2021-03-29 ZA ZA2021/02093A patent/ZA202102093B/en unknown
- 2021-09-02 US US17/464,815 patent/US20230001004A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017003273A1 (es) | Inmunoglobulinas conjugadas en cys80 | |
ECSP18095014A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
EA201890028A1 (ru) | Антитело, связывающее cd3 человека | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
NZ739721A (en) | Antigen binding constructs to target molecules | |
EA201491569A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
BR112019007288A2 (pt) | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente | |
BR112019003129A2 (pt) | composição compreendendo um domínio de ligação a antígeno que se liga a tigit humano, composição de ácido nucleico e de vetor de expressão, célula hospedeira, e, métodos para preparação de um anticorpo anti-tigit e para tratar cancer. | |
AR110526A1 (es) | Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer | |
CO2018011195A2 (es) | Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
CL2017000954A1 (es) | Moléculas de unión a antígeno biespecificas activadoras de células t | |
AR109771A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
EA201990331A1 (ru) | Мультиспецифические антигенсвязывающие белки и способы их применения | |
PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
BR112016014022A2 (pt) | anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit | |
EA201691827A1 (ru) | Конкретные участки для модификации антител с целью получения иммуноконъюгатов | |
EA201591814A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ Fc | |
CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
WO2012064733A3 (en) | Antibody scaffold for homogenous conjugation | |
CO6700829A2 (es) | Moduladores novedosos y métodos de uso | |
PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
EA201600277A1 (ru) | Высокоаффиные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |